BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 3158705)

  • 1. Regulation and deregulation of the fluid-phase classical pathway C3 convertase.
    Gigli I; Sorvillo J; Halbwachs-Mecarelli L
    J Immunol; 1985 Jul; 135(1):440-4. PubMed ID: 3158705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of action of the C4 nephritic factor. Deregulation of the classical pathway of C3 convertase.
    Gigli I; Sorvillo J; Mecarelli-Halbwachs L; Leibowitch J
    J Exp Med; 1981 Jul; 154(1):1-12. PubMed ID: 7019379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
    Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
    Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A model system for the study of the assembly and regulation of human complement C3 convertase (classical pathway).
    Thielens NM; Colomb MG
    Eur J Immunol; 1986 Jun; 16(6):617-22. PubMed ID: 3487454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
    Brown EJ; Ramsey J; Hammer CH; Frank MM
    J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of activation of the classical pathway of complement by monoclonal IgE (DES). Restricted regulation of C4b by C4b-binding protein.
    Saint-Remy JM
    Eur J Immunol; 1984 Mar; 14(3):254-9. PubMed ID: 6608450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of decay-accelerating factor on the assembly of the classical and alternative pathway C3 convertases in the presence of C4 or C3 nephritic factor.
    Ito S; Tamura N; Fujita T
    Immunology; 1989 Dec; 68(4):449-52. PubMed ID: 2481642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative resistance of the F-42-stabilized classical pathway C3 convertase to inactivation by C4-binding protein.
    Daha MR; van Es LA
    J Immunol; 1980 Nov; 125(5):2051-4. PubMed ID: 6903579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection.
    Fearon DT; Daha MR; Strom TB; Weiler JM; Carpenter CB; Austen KF
    Transplant Proc; 1977 Mar; 9(1):729-39. PubMed ID: 325806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistently circulating C3 nephritic factor (C3 NeF)-stabilized alternative pathway C3 convertase (C3 CoF) in serum of an 11-year-old girl with meningococcal septicemia--simultaneous occurrence with free C3 NeF.
    Wahn V; Müller W; Rieger C; Rother U
    Pediatr Res; 1987 Aug; 22(2):123-9. PubMed ID: 3658535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eosinophil granule major basic protein regulates generation of classical and alternative-amplification pathway C3 convertases in vitro.
    Weiler JM; Gleich GJ
    J Immunol; 1988 Mar; 140(5):1605-10. PubMed ID: 3346544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Formation of classical C3 convertase during the alternative pathway of human complement activation].
    Kozlov LV; Shibanova ED; Zinchenko AA
    Biokhimiia; 1987 Apr; 52(4):660-6. PubMed ID: 3647798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C3 nephritic factor (C3NeF): dissociation of cell-bound and fluid phase stabilization of alternative pathway C3 convertase.
    Ng YC; Peters DK
    Clin Exp Immunol; 1986 Aug; 65(2):450-7. PubMed ID: 3641695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assembly of the membrane attack complex promotes decay of the alternative pathway C3 convertase on Neisseria gonorrhoeae.
    Densen P; McRill CM; Ross SC
    J Immunol; 1988 Dec; 141(11):3902-9. PubMed ID: 3141507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A covalent dimer of complement C4b serves as a subunit of a novel C5 convertase that involves no C3 derivatives.
    Masaki T; Matsumoto M; Yasuda R; Levine RP; Kitamura H; Seya T
    J Immunol; 1991 Aug; 147(3):927-32. PubMed ID: 1861081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single arginine to tryptophan interchange at beta-chain residue 458 of human complement component C4 accounts for the defect in classical pathway C5 convertase activity of allotype C4A6. Implications for the location of a C5 binding site in C4.
    Ebanks RO; Jaikaran AS; Carroll MC; Anderson MJ; Campbell RD; Isenman DE
    J Immunol; 1992 May; 148(9):2803-11. PubMed ID: 1573269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator.
    Gigli I; Fujita T; Nussenzweig V
    Proc Natl Acad Sci U S A; 1979 Dec; 76(12):6596-600. PubMed ID: 293746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of the classical pathway of complement by the C3NeF-stabilized cell-bound amplification convertase.
    Daha MR; van Es LA
    J Immunol; 1979 Mar; 122(3):801-5. PubMed ID: 448075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative importance of C4 binding protein in the modulation of the classical pathway C3 convertase in patients with systemic lupus erythematosus.
    Daha MR; Hazevoet HM; Hermans J; van Es LA; Cats A
    Clin Exp Immunol; 1983 Oct; 54(1):248-52. PubMed ID: 6604610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of the classical complement pathway by nephritic factor bound to the alternative pathway C3/C5 convertase.
    Sobel AT; Cooper NR; Schreiber RD
    J Immunol; 1979 Jan; 122(1):34-8. PubMed ID: 762421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.